Radiolabelled Bisphosphonates for Bone Pain Palliation

  • Manfred Fischer
  • Willm Uwe Kampen
  • Valerie Lewington
Part of the Medical Radiology book series (MEDRAD)


This chapter deals with systemic radionuclide treatment of otherwise refractory bone pain in patients with bone metastases caused by different tumour diseases. It describes the different radiopharmaceuticals approved in Europe, both the indications and contraindications and the application procedure. Clinical results with significant pain palliation in 70–80 % of patients are reported in many studies. Finally, some promising results of recent studies, shifting the therapeutic goal from pure pain palliation towards tumoricidal effects by using new radiopharmaceuticals, combining radionuclides with chemotherapy or application of other treatment protocols are discussed.


Bone Metastasis Radionuclide Therapy Castration Resistant Prostate Cancer Painful Bone Metastasis Metastatic Castration Resistant Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Atkins HL, Mausner LF, Srivastava SC, Meinken GE et al (1995) Tin-117 m(4 +)-DTPA for palliation of pain from osseous metstases: a pilot study. J Nucl Med 36:725–729PubMedGoogle Scholar
  2. Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Canc Suppl 72:3443–3451CrossRefGoogle Scholar
  3. Baziotis N, Yakoumakis E, Zissimopoulos A et al (1998) Strontium-89 chloride in the treatment of bone metatases from breast cancer. Oncology 55:377–381PubMedCrossRefGoogle Scholar
  4. Blake GM, Zivanovic MA, McEwan AJB, Ackery DM (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454PubMedGoogle Scholar
  5. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ et al (1993) Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metatases secondary to prostate cancer: preliminary report of a multicente trial. Semin Oncol 20(suppl. 2):32–33PubMedGoogle Scholar
  6. Bouchet LG, Bolch WE, Goddu SM et al (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 41:682–687PubMedGoogle Scholar
  7. Brenner W, Kampen WU, Kampen AM, Henze E (2001) Skeletal uptake and soft tissue retention of 186-Re-HEDP and 153-Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 42:231–236Google Scholar
  8. Brucer M (1990) A chronology of nuclear medicine. Heritage Publ St, LouisGoogle Scholar
  9. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594PubMedCrossRefGoogle Scholar
  10. Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Canc 77:336–340CrossRefGoogle Scholar
  11. Collins C, Eary JF, Donaldson G et al (1993) Samarium-153 EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34:1839–1844PubMedGoogle Scholar
  12. Deguchi T, Yang M, Ehara H et al (1997) Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Canc 75:634–638CrossRefGoogle Scholar
  13. deKlerk JMH (1995) Re-186-HEDP in treatment of metatatic bone disease: pharmakokinetics and toxicity. Ponson & Looigen-Verlag, WagenningenGoogle Scholar
  14. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501–1504PubMedCrossRefGoogle Scholar
  15. Elgazzar AH, Maxon HR (1993) Radioisotope therapy of cancer related bone pain. In: Limouris GS, Shukla SK (eds.) Radionuclides for therapy. Mediterra Publishers, Athen S. 111–116Google Scholar
  16. Fettich J, Padhy A, Nair N et al (2003) Coparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metatatic bone pain: results of an IAEA coordinated research project. World J Nucl Med 2:226–231Google Scholar
  17. Fischer M (1999) Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 38:270–272PubMedGoogle Scholar
  18. Fuster D, Herranz R, Vidal-Sicart S et al (2000) Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 21:623–626PubMedCrossRefGoogle Scholar
  19. Galasko CSB (1982) Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169:20–27PubMedGoogle Scholar
  20. Geldof AA, de Rooij L, Versteegh RT et al (1999) Combination 186-Re-HEDP and cisplatin supraadditive treatment effects in prostate cancer cells. J Nucl Med 40:667–671PubMedGoogle Scholar
  21. Goddu SM, Bbishayee A, Bouchet LG et al (2000) Marrow toxicity of 33-P versus 32-P-orthophosphate: implication for therapy of bone pain and bone metastases. J Nucl Med 41:941–951PubMedGoogle Scholar
  22. Hillegonds DJ, Franklin S, Shelton DK et al. (2007) The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 99:785–794)Google Scholar
  23. Kalesnikov-Gauthier H, Carpenier P, Depreux P et al (2000) Evaluation of toxicity and efficacy of 186-Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41:1689–1694Google Scholar
  24. Kasalický J, Kraská V (1998) The effect of repeated strontium-89 chloride therapy in bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25:1362–1367PubMedCrossRefGoogle Scholar
  25. Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT (1997) Diagnostic bone scanning in oncology. Semin Nucl Med 27:107–141PubMedCrossRefGoogle Scholar
  26. Krishnamurthy GT, Krishnamurthy S (2000) Invited commentary: Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millenium. J Nucl Med 41:688–691PubMedGoogle Scholar
  27. Lau WF, Hicks R, Binns D (2001) Differential effects of bisphosphonate on Paget′s disease and metastatic prostatic carcinoma bone scan findings. Clin Nucl Med 26:347–348PubMedCrossRefGoogle Scholar
  28. Liepe K, Franke W-G, Koch R et al (2000) Comparison of Rhenium-188, Rhenium-186 and Strontium in palliation of painful bone metastases. Nuklearmedizin 39:146–151PubMedGoogle Scholar
  29. Malmberg I, Persson U, Ask A et al (1997) Painful bone metastases in hormon-refractory prostate cancer: economic cost of strontium-89 and/or external radiotherapy. Urology 50:747–753PubMedCrossRefGoogle Scholar
  30. Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, Diestelhorst S, Minami C (2002) Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153-EDTMP. Clin Nucl Med 27:427–430PubMedCrossRefGoogle Scholar
  31. Maxon HR, Deutsch EA, Thomas SR, Libson K (1988) Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 166:501–507PubMedCrossRefGoogle Scholar
  32. McCready VR, O′Sullivan J, Dearnaly D, Cook G (2002) Prediction of response of skeletal metastases from cancer of the prostate to high activity 186-Re HEDP therapy. J Nucl Med 43(suppl. 316):79–86 (abstract)Google Scholar
  33. McEwan AJB (1994) Palliation of bone pain. In: Murray IPC, Ell PJ (Hrsg) Nuclear medicine in clinical diagnosis and treatment. Churchill Livingston, Edinburgh, S 877–892Google Scholar
  34. McEwan AJB et al (1994) A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur J Urol 26(suppl 1):26–31Google Scholar
  35. Nilsson S, Franzen L, Parker C et al (2007) Bone targeted radium-223 in symptomatic, hormone refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587–594PubMedCrossRefGoogle Scholar
  36. O’Sullivan JM, McCready VR, Flux G et al (2002) High activity rhenium-186 HEDP with autologous blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Canc 86:1715–1720CrossRefGoogle Scholar
  37. Palmedo H, Manka-Waluch A, Albers P et al (2003) Repeated bon-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869–2875PubMedCrossRefGoogle Scholar
  38. Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Publ Pharmacol 2:117–149Google Scholar
  39. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D, Setoain J (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24:1210–1214PubMedCrossRefGoogle Scholar
  40. Porter AT, McEwan AJB, Powe JE, Reid R et al (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local external beam irradiation in the managemant of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 25:805–813CrossRefGoogle Scholar
  41. Resche I, Chatal JF, Pecking A et al (1997) A dose controlled study of Sm-153 ethylenediaminetetramethylene phosphonate in the treatment of patients with painful bone metastases. Eur J Canc 33(10):1583–1591CrossRefGoogle Scholar
  42. Roodman GD (1997) Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557–1514PubMedCrossRefGoogle Scholar
  43. Sciuto R, Tofani A, Festa A et al (2000) Short- and long-term effects of 186-Re-1,-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41:647–654PubMedGoogle Scholar
  44. Sciuto R, Festa A, Rea S et al (2002) Effects of low-dose Cisplatin on 89-Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79–86PubMedGoogle Scholar
  45. Serafini AN (2001) Therapy of metstatic bone pain. J Nucl Med 42:895–906PubMedGoogle Scholar
  46. Singh A, Holmes RA, Farhangi M, Volkert WA (1989) Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818PubMedGoogle Scholar
  47. Srivastava SC (2004) Treatment of bone and joint pain with electron emitting radiopharmaceuticals. Int J Nucl Med Biol 19:89–97Google Scholar
  48. Srivastava SC, Meinken GE, Li Z et al (2002) A novel sythetic method for preparing Sn-117 m Stannic DTPA for therapeutic use. J Nucl Med 43:372PGoogle Scholar
  49. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597PubMedGoogle Scholar
  50. Tu SM, Delpass ES, Jones D et al (1997) Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer. Urol Oncol 2:191–197CrossRefGoogle Scholar
  51. Tu SM, Millikan RE, Mengistu B et al (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357:336–341PubMedCrossRefGoogle Scholar
  52. Wagner G (1984) Frequency of pain in patients with cancer. Recent Results Canc Res 89:64–71CrossRefGoogle Scholar
  53. World Health Organisation (1990) Cancer pain relief and palliative care. WHO Tech Rep Ser 804:7–73Google Scholar
  54. Zyskowski A, Lamb D, Morum P et al (2001) Strontium-89 treatment for prostate cancer bone metastases: does a protate specific antigen response predict for improved survival? Aust Radiol 45:39–42CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Manfred Fischer
    • 1
  • Willm Uwe Kampen
    • 2
  • Valerie Lewington
    • 3
  1. 1.Praxis für RadiologieUnd NuklearmedizinKasselGermany
  2. 2.Nuclear Medicine SpitalerhofHamburgGermany
  3. 3.Nuclear Medicine DepartmentGuy’s and St Thomas’ HospitalLondonUK

Personalised recommendations